Skip to main content

Table 2 The most predictive peaks for delta heightSDS 0-2 year identified by regression analysis

From: Proteins related to lipoprotein profile were identified using a pharmaco-proteomic approach as markers for growth response to growth hormone (GH) treatment in short prepubertal children

Group Patients (n=) Peaks (n=) R 2 Cross-validated R 2 p-value Peak m/z value (kDa)
GHD 39 7 0,73 0,61 0,032 3.160, 3.318, 8.767 (Apo A-II), 9.135, 9.642, 12.872 (TTR),
17.390 (Apo A-II)
GHD 39 4 0,64 0,53 0,017 4.408 (Apo A-II), 8.696 (Apo A-II), 9.019 (Apo A-II),
17.146 (Apo A-II)
ISS 89 8 0,47 0,35 0,015 3.160, 4.470, 6.857 (Apo C-I), 8.767 (Apo A-II), 8.875 (Apo A-II), 9.425 (Apo C-III), 12.607 (SAA4), 12.872 (TTR)
Total 128 8 0,38 0,28 0,003 4.628, 4.470, 4.793, 8.817, 8.875, 9.019, 12.872, 17.146
GHD 39 4 0,59 0,48 0,026 4.138, 8.817 (Apo A-II), 9.019 (Apo A-II), 17.262 (Apo A-II)
Total 128 8 0,35 0,24 0,003 4.138, 8.636 (Apo A-II), 8.875 (Apo A-II), 9.135, 9.425
(Apo C-III), 14.055 (TTR), 28.090 (Apo A-I), 29.003
  1. GHD, GH-deficient; ISS, idiopathic short stature.
  2. The most predictive peaks identified by regression analysis at start, after 1 year, and during the first year of GH treatment. For each model, the R2-value and cross-validated R2 are presented.